 Jennifer Kiser
Concepts (348)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antiviral Agents | 30 | 2023 | 654 | 6.740 |
Why?
| | Anti-HIV Agents | 32 | 2023 | 664 | 4.750 |
Why?
| | Hepatitis C | 13 | 2023 | 217 | 4.710 |
Why?
| | HIV Infections | 53 | 2023 | 2459 | 4.630 |
Why?
| | Adenine | 27 | 2022 | 223 | 4.250 |
Why?
| | Ribavirin | 15 | 2020 | 88 | 4.160 |
Why?
| | Hepatitis C, Chronic | 13 | 2023 | 151 | 4.140 |
Why?
| | Sofosbuvir | 12 | 2023 | 52 | 3.850 |
Why?
| | Drug Interactions | 21 | 2019 | 352 | 3.670 |
Why?
| | Tenofovir | 28 | 2022 | 200 | 3.230 |
Why?
| | Tandem Mass Spectrometry | 16 | 2023 | 421 | 2.620 |
Why?
| | Hepacivirus | 10 | 2023 | 230 | 2.110 |
Why?
| | Proline | 5 | 2019 | 71 | 2.090 |
Why?
| | Oligopeptides | 8 | 2015 | 252 | 1.940 |
Why?
| | Dried Blood Spot Testing | 12 | 2023 | 68 | 1.900 |
Why?
| | Organophosphates | 13 | 2022 | 90 | 1.870 |
Why?
| | Organophosphonates | 12 | 2014 | 94 | 1.730 |
Why?
| | Ritonavir | 8 | 2021 | 70 | 1.600 |
Why?
| | Protease Inhibitors | 4 | 2020 | 102 | 1.540 |
Why?
| | Emtricitabine | 17 | 2021 | 146 | 1.490 |
Why?
| | Chromatography, Liquid | 13 | 2023 | 355 | 1.410 |
Why?
| | Phosphorous Acids | 3 | 2019 | 12 | 1.330 |
Why?
| | Benzimidazoles | 5 | 2020 | 140 | 1.300 |
Why?
| | Coinfection | 4 | 2018 | 119 | 1.230 |
Why?
| | Fluorenes | 4 | 2020 | 37 | 1.210 |
Why?
| | Pyrophosphatases | 3 | 2016 | 22 | 1.190 |
Why?
| | Nucleotides | 3 | 2016 | 112 | 1.180 |
Why?
| | Medication Adherence | 16 | 2022 | 556 | 1.050 |
Why?
| | Anti-Retroviral Agents | 5 | 2019 | 208 | 1.040 |
Why?
| | Drug Therapy, Combination | 11 | 2018 | 965 | 0.950 |
Why?
| | Hepatitis B | 3 | 2022 | 52 | 0.940 |
Why?
| | Pyridines | 5 | 2015 | 440 | 0.930 |
Why?
| | Erythrocytes | 8 | 2016 | 641 | 0.860 |
Why?
| | Polyphosphates | 7 | 2022 | 32 | 0.860 |
Why?
| | Humans | 96 | 2023 | 118974 | 0.850 |
Why?
| | Cell Phone | 1 | 2022 | 81 | 0.820 |
Why?
| | Reverse Transcriptase Inhibitors | 5 | 2014 | 81 | 0.820 |
Why?
| | HIV Protease Inhibitors | 5 | 2011 | 64 | 0.820 |
Why?
| | Membrane Transport Proteins | 4 | 2016 | 137 | 0.800 |
Why?
| | HIV-1 | 7 | 2021 | 776 | 0.790 |
Why?
| | Simeprevir | 2 | 2018 | 9 | 0.790 |
Why?
| | Sulfonamides | 5 | 2019 | 445 | 0.790 |
Why?
| | Mobile Applications | 1 | 2022 | 147 | 0.750 |
Why?
| | Therapies, Investigational | 1 | 2019 | 14 | 0.720 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 2020 | 99 | 0.690 |
Why?
| | Heterocyclic Compounds, 3-Ring | 2 | 2023 | 28 | 0.690 |
Why?
| | Ethanol | 1 | 2023 | 575 | 0.660 |
Why?
| | Male | 51 | 2023 | 57801 | 0.650 |
Why?
| | Adult | 40 | 2021 | 31512 | 0.650 |
Why?
| | Lung Transplantation | 1 | 2020 | 263 | 0.640 |
Why?
| | Middle Aged | 35 | 2020 | 27617 | 0.640 |
Why?
| | Pyridazines | 2 | 2021 | 50 | 0.640 |
Why?
| | Antiretroviral Therapy, Highly Active | 4 | 2015 | 260 | 0.630 |
Why?
| | Solid Phase Extraction | 2 | 2014 | 19 | 0.620 |
Why?
| | Leukocytes, Mononuclear | 8 | 2021 | 509 | 0.610 |
Why?
| | Pyrimidinones | 2 | 2008 | 86 | 0.600 |
Why?
| | Liver | 2 | 2016 | 1816 | 0.590 |
Why?
| | HIV Integrase Inhibitors | 1 | 2018 | 60 | 0.590 |
Why?
| | Viral Load | 10 | 2023 | 419 | 0.590 |
Why?
| | Inosine | 1 | 2016 | 12 | 0.580 |
Why?
| | Guanosine | 1 | 2016 | 39 | 0.570 |
Why?
| | Pharmacogenomic Variants | 1 | 2016 | 35 | 0.570 |
Why?
| | Chromatography, High Pressure Liquid | 2 | 2015 | 490 | 0.540 |
Why?
| | Purines | 1 | 2016 | 161 | 0.540 |
Why?
| | Female | 45 | 2023 | 61565 | 0.540 |
Why?
| | Drug Monitoring | 3 | 2022 | 187 | 0.530 |
Why?
| | Drug Discovery | 1 | 2016 | 124 | 0.530 |
Why?
| | Isoniazid | 2 | 2012 | 53 | 0.520 |
Why?
| | Serum | 1 | 2015 | 63 | 0.510 |
Why?
| | Adenosine | 1 | 2016 | 211 | 0.510 |
Why?
| | Kidney | 4 | 2016 | 1353 | 0.500 |
Why?
| | Intracellular Space | 1 | 2014 | 69 | 0.500 |
Why?
| | Telemedicine | 1 | 2022 | 664 | 0.490 |
Why?
| | Pre-Exposure Prophylaxis | 5 | 2020 | 174 | 0.490 |
Why?
| | Antitubercular Agents | 2 | 2012 | 163 | 0.480 |
Why?
| | HIV | 4 | 2019 | 210 | 0.480 |
Why?
| | Deoxycytidine | 6 | 2017 | 136 | 0.480 |
Why?
| | Priapism | 1 | 2013 | 9 | 0.470 |
Why?
| | Adrenergic alpha-Antagonists | 1 | 2013 | 31 | 0.470 |
Why?
| | Receptors, Adrenergic, alpha | 1 | 2013 | 32 | 0.470 |
Why?
| | Cytochrome P-450 CYP3A Inhibitors | 1 | 2013 | 17 | 0.470 |
Why?
| | Hepatitis B, Chronic | 3 | 2022 | 18 | 0.440 |
Why?
| | Gastric Bypass | 1 | 2014 | 93 | 0.440 |
Why?
| | Treatment Outcome | 12 | 2021 | 9342 | 0.420 |
Why?
| | Prospective Studies | 17 | 2022 | 6471 | 0.410 |
Why?
| | Phenotype | 2 | 2016 | 3003 | 0.400 |
Why?
| | Pyrimidines | 3 | 2021 | 382 | 0.390 |
Why?
| | HIV Seronegativity | 1 | 2010 | 24 | 0.390 |
Why?
| | Antacids | 1 | 2010 | 15 | 0.390 |
Why?
| | Pyrrolidinones | 1 | 2010 | 25 | 0.380 |
Why?
| | Hepatitis B virus | 3 | 2022 | 25 | 0.380 |
Why?
| | Patient Compliance | 3 | 2017 | 537 | 0.370 |
Why?
| | Genotype | 6 | 2023 | 1882 | 0.370 |
Why?
| | Tuberculosis | 2 | 2012 | 240 | 0.370 |
Why?
| | Pharmacy Service, Hospital | 1 | 2011 | 86 | 0.370 |
Why?
| | Blood Chemical Analysis | 4 | 2019 | 95 | 0.360 |
Why?
| | Reproducibility of Results | 8 | 2016 | 2874 | 0.350 |
Why?
| | Plasma | 4 | 2016 | 224 | 0.350 |
Why?
| | Area Under Curve | 4 | 2018 | 296 | 0.350 |
Why?
| | Uridine Monophosphate | 2 | 2019 | 15 | 0.340 |
Why?
| | Drug Prescriptions | 1 | 2011 | 248 | 0.330 |
Why?
| | Adolescent | 19 | 2020 | 18480 | 0.330 |
Why?
| | Fluorobenzenes | 1 | 2008 | 13 | 0.330 |
Why?
| | Young Adult | 16 | 2020 | 10793 | 0.320 |
Why?
| | Drug Stability | 5 | 2016 | 153 | 0.310 |
Why?
| | Guidelines as Topic | 1 | 2009 | 262 | 0.300 |
Why?
| | Atazanavir Sulfate | 5 | 2015 | 41 | 0.300 |
Why?
| | Liver Transplantation | 1 | 2014 | 847 | 0.290 |
Why?
| | Sensitivity and Specificity | 5 | 2014 | 1795 | 0.290 |
Why?
| | Half-Life | 3 | 2015 | 147 | 0.290 |
Why?
| | Glycerophospholipids | 2 | 2023 | 29 | 0.290 |
Why?
| | Alanine | 3 | 2021 | 102 | 0.290 |
Why?
| | Esomeprazole | 1 | 2006 | 6 | 0.280 |
Why?
| | Anti-Ulcer Agents | 1 | 2006 | 16 | 0.280 |
Why?
| | Pharmacology, Clinical | 1 | 2006 | 8 | 0.280 |
Why?
| | Carbamates | 1 | 2006 | 37 | 0.280 |
Why?
| | Sustained Virologic Response | 3 | 2023 | 33 | 0.280 |
Why?
| | Hepatocytes | 3 | 2016 | 205 | 0.270 |
Why?
| | Education | 1 | 2006 | 105 | 0.260 |
Why?
| | Proton Pump Inhibitors | 1 | 2006 | 98 | 0.260 |
Why?
| | South Africa | 4 | 2015 | 163 | 0.260 |
Why?
| | Biomarkers | 5 | 2023 | 3588 | 0.250 |
Why?
| | Phosphates | 3 | 2015 | 167 | 0.240 |
Why?
| | Anemia | 2 | 2016 | 146 | 0.240 |
Why?
| | Health Personnel | 1 | 2009 | 588 | 0.230 |
Why?
| | Variola virus | 1 | 2022 | 1 | 0.230 |
Why?
| | Smallpox | 1 | 2022 | 7 | 0.220 |
Why?
| | Cross-Over Studies | 4 | 2020 | 456 | 0.210 |
Why?
| | World Health Organization | 1 | 2022 | 107 | 0.210 |
Why?
| | Delivery of Health Care | 1 | 2009 | 867 | 0.210 |
Why?
| | Cyclopropanes | 2 | 2019 | 80 | 0.210 |
Why?
| | Linear Models | 2 | 2014 | 827 | 0.200 |
Why?
| | Lopinavir | 3 | 2020 | 29 | 0.200 |
Why?
| | Point-of-Care Systems | 1 | 2023 | 151 | 0.200 |
Why?
| | Dideoxynucleosides | 2 | 2023 | 20 | 0.200 |
Why?
| | Interferons | 2 | 2019 | 151 | 0.200 |
Why?
| | Phosphorylation | 2 | 2015 | 1633 | 0.190 |
Why?
| | Aminoisobutyric Acids | 1 | 2019 | 8 | 0.180 |
Why?
| | Drug Administration Schedule | 3 | 2019 | 736 | 0.180 |
Why?
| | Lactams, Macrocyclic | 1 | 2019 | 47 | 0.180 |
Why?
| | Pyrrolidines | 1 | 2019 | 57 | 0.180 |
Why?
| | Homosexuality, Male | 2 | 2017 | 166 | 0.170 |
Why?
| | Quinoxalines | 1 | 2019 | 62 | 0.170 |
Why?
| | Leucine | 1 | 2019 | 117 | 0.170 |
Why?
| | Nucleic Acids | 1 | 2019 | 59 | 0.170 |
Why?
| | Pregnancy Complications, Infectious | 2 | 2020 | 296 | 0.160 |
Why?
| | Organic Anion Transport Protein 1 | 2 | 2008 | 6 | 0.160 |
Why?
| | Quality Control | 2 | 2015 | 159 | 0.160 |
Why?
| | Oxazines | 1 | 2018 | 25 | 0.160 |
Why?
| | Multidrug Resistance-Associated Proteins | 2 | 2008 | 36 | 0.160 |
Why?
| | Directly Observed Therapy | 1 | 2017 | 14 | 0.160 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2020 | 613 | 0.160 |
Why?
| | Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | 1 | 2017 | 14 | 0.160 |
Why?
| | Liver Cirrhosis | 1 | 2019 | 245 | 0.150 |
Why?
| | Nitriles | 2 | 2021 | 155 | 0.150 |
Why?
| | Pharmacogenetics | 2 | 2016 | 151 | 0.150 |
Why?
| | Pregnancy Outcome | 1 | 2020 | 349 | 0.150 |
Why?
| | Inosine Triphosphate | 1 | 2016 | 3 | 0.150 |
Why?
| | Anemia, Hemolytic | 1 | 2016 | 19 | 0.150 |
Why?
| | Darunavir | 2 | 2014 | 17 | 0.150 |
Why?
| | Deoxyadenine Nucleotides | 1 | 2016 | 13 | 0.150 |
Why?
| | Deoxycytosine Nucleotides | 1 | 2016 | 11 | 0.150 |
Why?
| | Zika Virus | 1 | 2017 | 61 | 0.150 |
Why?
| | Molecular Targeted Therapy | 1 | 2019 | 356 | 0.150 |
Why?
| | Pyridones | 1 | 2018 | 119 | 0.150 |
Why?
| | Pharmacy | 1 | 2017 | 30 | 0.150 |
Why?
| | Guanosine Triphosphate | 1 | 2016 | 87 | 0.150 |
Why?
| | Glass | 1 | 2016 | 44 | 0.150 |
Why?
| | Genitalia | 1 | 2016 | 27 | 0.140 |
Why?
| | Syringes | 1 | 2016 | 37 | 0.140 |
Why?
| | Disease Transmission, Infectious | 1 | 2017 | 56 | 0.140 |
Why?
| | Drug and Narcotic Control | 1 | 2016 | 28 | 0.140 |
Why?
| | Viremia | 3 | 2022 | 132 | 0.140 |
Why?
| | Drug Packaging | 1 | 2016 | 44 | 0.140 |
Why?
| | Retrospective Studies | 4 | 2020 | 12978 | 0.140 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2011 | 387 | 0.140 |
Why?
| | Mental Health Services | 1 | 2019 | 331 | 0.130 |
Why?
| | Fibroblast Growth Factors | 2 | 2014 | 175 | 0.130 |
Why?
| | Polymers | 1 | 2019 | 482 | 0.130 |
Why?
| | Analgesics | 1 | 2017 | 159 | 0.130 |
Why?
| | Rectum | 1 | 2016 | 157 | 0.130 |
Why?
| | Cytosol | 1 | 2016 | 221 | 0.130 |
Why?
| | Piperazines | 1 | 2018 | 316 | 0.130 |
Why?
| | Practice Guidelines as Topic | 2 | 2016 | 1440 | 0.130 |
Why?
| | Biological Assay | 1 | 2016 | 122 | 0.130 |
Why?
| | Creatinine | 2 | 2018 | 491 | 0.130 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2016 | 2062 | 0.130 |
Why?
| | Virus Replication | 1 | 2017 | 405 | 0.130 |
Why?
| | Population | 1 | 2015 | 30 | 0.130 |
Why?
| | Nonlinear Dynamics | 1 | 2015 | 89 | 0.130 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2016 | 136 | 0.130 |
Why?
| | Brain Diseases | 1 | 2016 | 140 | 0.130 |
Why?
| | Liver Function Tests | 1 | 2015 | 107 | 0.130 |
Why?
| | CD4 Lymphocyte Count | 2 | 2015 | 267 | 0.120 |
Why?
| | Adenosine Triphosphate | 1 | 2016 | 439 | 0.120 |
Why?
| | Pharmacists | 1 | 2017 | 238 | 0.120 |
Why?
| | Infant | 5 | 2020 | 8293 | 0.120 |
Why?
| | Least-Squares Analysis | 1 | 2014 | 73 | 0.120 |
Why?
| | Administration, Oral | 3 | 2019 | 756 | 0.120 |
Why?
| | Pharmaceutical Preparations | 1 | 2016 | 167 | 0.120 |
Why?
| | Metabolic Clearance Rate | 2 | 2018 | 113 | 0.120 |
Why?
| | Double-Blind Method | 3 | 2013 | 1687 | 0.120 |
Why?
| | Hypophosphatemia | 1 | 2013 | 21 | 0.120 |
Why?
| | Cholecalciferol | 1 | 2014 | 51 | 0.120 |
Why?
| | Liver Diseases | 1 | 2016 | 282 | 0.120 |
Why?
| | Diphosphates | 3 | 2021 | 16 | 0.120 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2013 | 60 | 0.110 |
Why?
| | Calcitriol | 1 | 2013 | 55 | 0.110 |
Why?
| | Tablets | 2 | 2023 | 35 | 0.110 |
Why?
| | Leukocytes | 1 | 2014 | 290 | 0.110 |
Why?
| | Desiccation | 1 | 2012 | 17 | 0.110 |
Why?
| | Monocytes | 1 | 2015 | 513 | 0.110 |
Why?
| | Diabetes Mellitus | 1 | 2020 | 942 | 0.110 |
Why?
| | Child, Preschool | 4 | 2021 | 9491 | 0.110 |
Why?
| | Benzoxazines | 1 | 2012 | 28 | 0.110 |
Why?
| | Pravastatin | 1 | 2011 | 29 | 0.100 |
Why?
| | Organic Anion Transporters | 1 | 2011 | 19 | 0.100 |
Why?
| | Levonorgestrel | 1 | 2012 | 32 | 0.100 |
Why?
| | Kidney Diseases | 1 | 2016 | 439 | 0.100 |
Why?
| | Arylamine N-Acetyltransferase | 1 | 2011 | 5 | 0.100 |
Why?
| | Nucleosides | 1 | 2011 | 26 | 0.100 |
Why?
| | Mental Disorders | 1 | 2019 | 939 | 0.100 |
Why?
| | Vitamin D Deficiency | 1 | 2013 | 162 | 0.100 |
Why?
| | Specimen Handling | 1 | 2012 | 165 | 0.100 |
Why?
| | Interferon-alpha | 1 | 2012 | 191 | 0.100 |
Why?
| | Contraceptive Agents, Female | 1 | 2012 | 65 | 0.100 |
Why?
| | Patient Acceptance of Health Care | 1 | 2017 | 687 | 0.100 |
Why?
| | Raltegravir Potassium | 1 | 2010 | 16 | 0.100 |
Why?
| | Models, Statistical | 1 | 2015 | 636 | 0.100 |
Why?
| | Hospitals, University | 1 | 2011 | 172 | 0.090 |
Why?
| | Aged | 4 | 2018 | 19657 | 0.090 |
Why?
| | Body Weight | 1 | 2015 | 934 | 0.090 |
Why?
| | Dietary Supplements | 1 | 2014 | 467 | 0.090 |
Why?
| | Sex Characteristics | 1 | 2015 | 671 | 0.090 |
Why?
| | Cohort Studies | 2 | 2019 | 5116 | 0.090 |
Why?
| | Sex Distribution | 1 | 2011 | 351 | 0.090 |
Why?
| | Mycobacterium tuberculosis | 1 | 2012 | 266 | 0.090 |
Why?
| | Drug Combinations | 2 | 2020 | 291 | 0.090 |
Why?
| | Time Factors | 4 | 2016 | 6412 | 0.080 |
Why?
| | Lamivudine | 2 | 2023 | 59 | 0.080 |
Why?
| | Rosuvastatin Calcium | 1 | 2008 | 19 | 0.080 |
Why?
| | Immunosuppressive Agents | 1 | 2012 | 681 | 0.080 |
Why?
| | Kidney Calculi | 1 | 2007 | 33 | 0.070 |
Why?
| | Portugal | 1 | 2006 | 9 | 0.070 |
Why?
| | Case-Control Studies | 2 | 2020 | 3171 | 0.070 |
Why?
| | Gene Frequency | 1 | 2008 | 513 | 0.070 |
Why?
| | Self Report | 2 | 2021 | 699 | 0.070 |
Why?
| | Quebec | 1 | 2006 | 5 | 0.070 |
Why?
| | Furans | 1 | 2006 | 23 | 0.070 |
Why?
| | Dementia | 1 | 2009 | 208 | 0.070 |
Why?
| | Education, Medical | 1 | 2009 | 239 | 0.070 |
Why?
| | Referral and Consultation | 1 | 2011 | 648 | 0.070 |
Why?
| | Sexual and Gender Minorities | 2 | 2019 | 137 | 0.070 |
Why?
| | United States | 4 | 2017 | 12555 | 0.070 |
Why?
| | Infectious Disease Transmission, Vertical | 2 | 2020 | 156 | 0.070 |
Why?
| | Internationality | 1 | 2006 | 152 | 0.060 |
Why?
| | Child | 4 | 2021 | 19129 | 0.060 |
Why?
| | Hematocrit | 2 | 2016 | 91 | 0.060 |
Why?
| | Lipids | 1 | 2008 | 607 | 0.060 |
Why?
| | Predictive Value of Tests | 2 | 2019 | 1868 | 0.060 |
Why?
| | Isoindoles | 1 | 2022 | 6 | 0.060 |
Why?
| | Monkeypox virus | 1 | 2022 | 12 | 0.060 |
Why?
| | Risk Assessment | 1 | 2012 | 3057 | 0.050 |
Why?
| | Calibration | 2 | 2013 | 135 | 0.050 |
Why?
| | Benzamides | 1 | 2022 | 176 | 0.050 |
Why?
| | Animals | 4 | 2022 | 33381 | 0.050 |
Why?
| | Demography | 1 | 2022 | 274 | 0.050 |
Why?
| | Temperature | 2 | 2016 | 622 | 0.050 |
Why?
| | Treatment Failure | 1 | 2023 | 341 | 0.050 |
Why?
| | Computer Simulation | 2 | 2016 | 922 | 0.050 |
Why?
| | Pregnancy | 3 | 2020 | 5691 | 0.050 |
Why?
| | Tissue Donors | 1 | 2023 | 336 | 0.050 |
Why?
| | Drug Approval | 1 | 2020 | 77 | 0.050 |
Why?
| | Lactation | 1 | 2020 | 160 | 0.040 |
Why?
| | Benchmarking | 1 | 2020 | 172 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2016 | 1945 | 0.040 |
Why?
| | Developing Countries | 1 | 2020 | 255 | 0.040 |
Why?
| | Models, Biological | 2 | 2016 | 1715 | 0.040 |
Why?
| | Chemistry Techniques, Analytical | 1 | 2018 | 18 | 0.040 |
Why?
| | Flaviviridae | 1 | 2017 | 4 | 0.040 |
Why?
| | Drug Repositioning | 1 | 2017 | 14 | 0.040 |
Why?
| | Hair | 1 | 2018 | 68 | 0.040 |
Why?
| | A549 Cells | 1 | 2017 | 48 | 0.040 |
Why?
| | Vero Cells | 1 | 2017 | 69 | 0.040 |
Why?
| | Inhibitory Concentration 50 | 1 | 2017 | 81 | 0.040 |
Why?
| | Alcohol Drinking | 1 | 2023 | 652 | 0.040 |
Why?
| | Breast Feeding | 1 | 2020 | 386 | 0.040 |
Why?
| | Pharmaceutical Solutions | 1 | 2016 | 14 | 0.040 |
Why?
| | Chromatography, Reverse-Phase | 1 | 2016 | 25 | 0.040 |
Why?
| | Cities | 1 | 2017 | 96 | 0.040 |
Why?
| | Drug Storage | 1 | 2016 | 59 | 0.040 |
Why?
| | Patient Selection | 1 | 2020 | 676 | 0.040 |
Why?
| | Defective Viruses | 1 | 2016 | 4 | 0.040 |
Why?
| | Acute Disease | 1 | 2019 | 940 | 0.040 |
Why?
| | Drug Compounding | 1 | 2016 | 90 | 0.040 |
Why?
| | Solubility | 1 | 2016 | 235 | 0.030 |
Why?
| | Methanol | 1 | 2016 | 35 | 0.030 |
Why?
| | Cold Temperature | 1 | 2016 | 132 | 0.030 |
Why?
| | Spermatozoa | 1 | 2016 | 91 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2020 | 969 | 0.030 |
Why?
| | Blood-Brain Barrier | 1 | 2016 | 108 | 0.030 |
Why?
| | Solutions | 1 | 2016 | 156 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2016 | 536 | 0.030 |
Why?
| | Pregnancy Complications | 1 | 2020 | 448 | 0.030 |
Why?
| | Administration, Inhalation | 1 | 2016 | 656 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2017 | 749 | 0.030 |
Why?
| | Risk-Taking | 1 | 2017 | 319 | 0.030 |
Why?
| | Comorbidity | 1 | 2019 | 1527 | 0.030 |
Why?
| | Logistic Models | 1 | 2020 | 1901 | 0.030 |
Why?
| | Recurrence | 1 | 2017 | 975 | 0.030 |
Why?
| | Mental Health | 1 | 2019 | 568 | 0.030 |
Why?
| | Interleukins | 1 | 2016 | 242 | 0.030 |
Why?
| | DNA, Viral | 1 | 2016 | 356 | 0.030 |
Why?
| | Vitamin D-Binding Protein | 1 | 2013 | 14 | 0.030 |
Why?
| | Algorithms | 1 | 2020 | 1541 | 0.030 |
Why?
| | Parathyroid Hormone | 1 | 2013 | 99 | 0.030 |
Why?
| | Water | 1 | 2016 | 425 | 0.030 |
Why?
| | Therapeutic Equivalency | 1 | 2012 | 18 | 0.030 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 245 | 0.030 |
Why?
| | Alkynes | 1 | 2012 | 56 | 0.030 |
Why?
| | Cell Line | 1 | 2017 | 2707 | 0.030 |
Why?
| | Anion Exchange Resins | 1 | 2011 | 7 | 0.030 |
Why?
| | Food-Drug Interactions | 1 | 2010 | 6 | 0.020 |
Why?
| | Zidovudine | 1 | 2011 | 77 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2018 | 2513 | 0.020 |
Why?
| | Reference Standards | 1 | 2011 | 176 | 0.020 |
Why?
| | Epithelial Cells | 1 | 2016 | 963 | 0.020 |
Why?
| | Chemoprevention | 1 | 2010 | 89 | 0.020 |
Why?
| | Latent Tuberculosis | 1 | 2011 | 69 | 0.020 |
Why?
| | Haplotypes | 1 | 2011 | 473 | 0.020 |
Why?
| | Cholesterol | 1 | 2011 | 373 | 0.020 |
Why?
| | Glomerular Filtration Rate | 1 | 2013 | 683 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2020 | 5255 | 0.020 |
Why?
| | Triglycerides | 1 | 2011 | 519 | 0.020 |
Why?
| | AIDS Dementia Complex | 1 | 2009 | 52 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2019 | 4552 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 4596 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2011 | 642 | 0.020 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2009 | 224 | 0.020 |
Why?
| | Positron-Emission Tomography | 1 | 2009 | 298 | 0.020 |
Why?
| | Calcium | 1 | 2013 | 1169 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2445 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2018 | 6561 | 0.020 |
Why?
| | Neuropsychological Tests | 1 | 2009 | 1032 | 0.020 |
Why?
| | Brain | 1 | 2016 | 2490 | 0.020 |
Why?
| | Age Factors | 1 | 2011 | 2995 | 0.010 |
Why?
| | Alzheimer Disease | 1 | 2009 | 513 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2009 | 3174 | 0.010 |
Why?
|
|
Kiser's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|